Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

3854 - Efficacy and safety of BCD-022, trastuzumab biosimilar candidate, compared to herceptin: Results of international multicenter randomized double blind study in patients with HER2+ mBC


09 Oct 2016


Breast cancer, metastatic


Maria Shustova


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


M. Shustova1, O. Burdaeva2, S. Alexeev3, K. Shelepen4, A. Khorinko5, G. Mukhametshina6, L. Sheveleva7, R. Ivanov1

Author affiliations

  • 1 Medical Department, JSC "BIOCAD", 198515 - St. Petersburg/RU
  • 2 Chemotherapy Department, Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk/RU
  • 3 Therapeutic Oncology, N.N.Petrov Research Inst. of Oncology, St. Petersburg/RU
  • 4 Oncology Department, Brest Regional Oncologic Dispensary, Brest/BY
  • 5 Chemotherapy Department, Perm Regional Oncological Dispensary, Perm/RU
  • 6 Chemotherapy Department, Kazan Clinical Oncology Center, Kazan/RU
  • 7 Chemotherapy Department, Volgograd Regional Oncologic Dispensary, Volgograd/RU


Abstract 3854


BCD-022 demonstrated equivalence to Herceptin in a comprehensive comparability physicochemical, non-clinical PK and PD studies, as well as phase I PK clinical study in patients with HER2+ mBC.


126 patients with HER2-positive metastatic BC were randomly assigned into 2 groups at a ratio of 1:1 to receive BCD-022 or Herceptin at a loading dose of 8 mg/kg and then in maintenance dose of 6 mg/kg in combination with paclitaxel (175 mg/m2) every 3 weeks up to 6 cycles of therapy or until progression or unbearable toxicity.


ORR (primary endpoint) in both groups had no statistically significant differences: 53.57% (95% CI 40.70 – 65.98%) in BCD-022 group and 53.70% (95% CI 40.60 – 66.31%) in Herceptin group. The lower limit of 95% CI for ORR difference between the groups (-19.83%) did not exceed the non-inferiority margin, hence BCD-022 is non-inferior to Herceptin. There were also no differences between the groups for all other efficacy parameters: CR (5.36 vs 3.70%), PR (48.21 vs 50.00%), SD (25.00 vs 25.93%) and progression rate (21.43 vs 20.37%) in BCD-022 and Herceptin group, respectively. AEs profiles of BCD-022 and Herceptin were equivalent. Rate of all observed AEs including severe AEs had no statistically significant difference between the groups. Most AEs were associated with chemotherapy: neutropenia (73.02 vs 73,77%), anemia (82.54 vs 77.05%), leukopenia (73.02 vs 68.85%), lymphopenia (69.84 vs. 65.57%), thrombocytopenia (17.46 vs 29.51%), hyperglycemia (57.14 vs 70.49%), ALP increase (38.68 vs 42.62%), AST increase (42.86 vs 42.62%), ALT increase (33.33 vs 40.98%), alopecia (33.33 vs 34.43%), arthralgia (17.46 vs 18.03%) etc. Cardiovascular events specific for trastuzumab included: tachycardia (34.92 vs 19.67%), arterial hypertension (20.63 vs 18.03%), atrial fibrillation (0 vs 3.28%), extrasystoles (0% vs 1.64%), CAD gr.1 (1.59 vs 0%) and aggravated myocardiodystrophy (1.59 vs 0%). Binding antibodies with neutralizing activity were detected only in 1 patient in each group that indicated to low immunogenic potential of both drugs.


BCD-022 demonstrated non-inferiority to Herceptin in patients with HER2+ mBC.

Clinical trial identification


Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings